Related Experiment Video
Updated: Aug 15, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Triphenyl phosphite neuropathy differs from organophosphorus-induced delayed neuropathy in rats
Abstract:
The topographies of neuropathic damage produced by triphenyl phosphite (TPP) and tri-ortho-cresyl phosphate (TOCP) are contrasted in the present study. Long-Evans, male rats were exposed (sc) to single (0.1 ml kg-1; 1.0 ml kg-1) or multiple (2 X 1.0 ml kg-1; 3 X 1.0 ml kg-1) doses of TPP, and sampled 1-3 weeks after exposure. Additional animals were dosed acutely with TOCP (1160 mg kg-1, p.o.) alone or in combination with multiple doses of TPP (2 X 1 ml kg-1). Functional changes, seen in multiple-dosed TPP-rats included tail-kinking, circling, and ataxia. Neuropathological damage seen in all but the 0.1 ml kg-1 treated animals consisted of degeneration of the ventrolateral and ventral columns of the spinal cord at all levels, and moderate peripheral nerve fibre damage. Medullary brainstem involvement consisted of axonal swellings and fragmented axons in the medial longitudinal fasciculus, the reticular formation, and the inferior cerebellar peduncles. Tissues examined from TOCP-treated rats displayed severe degeneration of the fasciculus gracilis at the cervical level, mild involvement of the dorsolateral columns at the lumbar levels and a sparing of all other cord and brainstem regions. Rats treated with neuropathic doses of both TPP and TOCP showed a composite pattern of degeneration that included damaged sites characteristic of the individual neurotoxicants. These data indicate that the neuropathic profile of TPP differs markedly from the delayed neuropathy (OPIDN) associated with exposure to model organophosphorus compounds such as TOCP.
More Related Videos
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
09:39Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...